Advertisement

Idiopathic Recurrent Acute Pericarditis

  • Apostolos KontziasEmail author
Chapter

Abstract

Recurrent pericarditis is idiopathic in majority of patients and is frequently precipitated by a well-defined trigger such as injury or infection. Rigorous invasive diagnostic workup is not indicated unless risk factors for secondary causes are present. Idiopathic recurrent acute pericarditis (IRAP) can rarely be complicated by myocarditis, constrictive pericarditis, and pericardial tamponade. IRAP’s pathophysiology shares features with the autoinflammatory syndromes; hence, colchicine and anakinra, an interleukin 1 receptor antagonist, have proven effective therapeutic strategies in patients refractory or intolerant to nonsteroid anti-inflammatory medications and steroids.

Keywords

Recurrent pericarditis Autoinflammatory Inflammasome Colchicine Anakinra Interleukin 1 

References

  1. 1.
    Cremer PC, Kumar A, Kontzias A, Tan CD, Rodriguez ER, Imazio M, et al. Complicated pericarditis: understanding risk factors and pathophysiology to inform imaging and treatment. J Am Coll Cardiol. 2016;68(21):2311–28.CrossRefGoogle Scholar
  2. 2.
    Imazio M, Gaita F. Diagnosis and treatment of pericarditis. Heart. 2015;101(14):1159–68.CrossRefGoogle Scholar
  3. 3.
    Imazio M, Gaita F, LeWinter M. Evaluation and treatment of pericarditis: a systematic review. JAMA. 2015;314(14):1498–506.CrossRefGoogle Scholar
  4. 4.
    Permanyer-Miralda G, Sagrista-Sauleda J, Soler-Soler J. Primary acute pericardial disease: a prospective series of 231 consecutive patients. Am J Cardiol. 1985;56(10):623–30.CrossRefGoogle Scholar
  5. 5.
    Ozen S, Demirkaya E, Amaryan G, Kone-Paut I, Polat A, Woo P, et al. Results from a multicentre international registry of familial Mediterranean fever: impact of environment on the expression of a monogenic disease in children. Ann Rheum Dis. 2014;73(4):662–7.CrossRefGoogle Scholar
  6. 6.
    Lachmann HJ, Papa R, Gerhold K, Obici L, Touitou I, Cantarini L, et al. The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. Ann Rheum Dis. 2014;73(12):2160–7.CrossRefGoogle Scholar
  7. 7.
    Cantarini L, Lucherini OM, Baldari CT, Laghi Pasini F, Galeazzi M. Familial clustering of recurrent pericarditis may disclose tumour necrosis factor receptor-associated periodic syndrome. Clin Exp Rheumatol. 2010;28(3):405–7.PubMedGoogle Scholar
  8. 8.
    Brucato A, Brambilla G. Recurrent idiopathic pericarditis: familial occurrence. Int J Cardiol. 2005;102(3):529.CrossRefGoogle Scholar
  9. 9.
    Cantarini L, Lucherini OM, Brucato A, Barone L, Cumetti D, Iacoponi F, et al. Clues to detect tumor necrosis factor receptor-associated periodic syndrome (TRAPS) among patients with idiopathic recurrent acute pericarditis: results of a multicentre study. Clin Res Cardiol. 2012;101(7):525–31.CrossRefGoogle Scholar
  10. 10.
    Cantarini L, Rigante D, Merlini G, Vitale A, Caso F, Lucherini OM, et al. The expanding spectrum of low-penetrance TNFRSF1A gene variants in adults presenting with recurrent inflammatory attacks: clinical manifestations and long-term follow-up. Semin Arthritis Rheum. 2014;43(6):818–23.CrossRefGoogle Scholar
  11. 11.
    Imazio M, Brucato A, Barbieri A, Ferroni F, Maestroni S, Ligabue G, et al. Good prognosis for pericarditis with and without myocardial involvement. Results from a multicenter, prospective cohort study. Circulation. 2013;128(1):42–9.CrossRefGoogle Scholar
  12. 12.
    Imazio M, Brucato A, Cemin R, Ferrua S, Belli R, Maestroni S, et al. Colchicine for recurrent pericarditis (CORP): a randomized trial. Ann Intern Med. 2011;155(7):409–14.CrossRefGoogle Scholar
  13. 13.
    Imazio M, Cecchi E, Demichelis B, Ierna S, Demarie D, Ghisio A, et al. Indicators of poor prognosis of acute pericarditis. Circulation. 2007;115(21):2739–44.CrossRefGoogle Scholar
  14. 14.
    Imazio M, Belli R, Brucato A, Cemin R, Ferrua S, Beqaraj F, et al. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. Lancet. 2014;383(9936):2232–7.CrossRefGoogle Scholar
  15. 15.
    Imazio M. Idiopathic recurrent pericarditis as an immune-mediated disease: current insights into pathogenesis and emerging treatment options. Expert Rev Clin Immunol. 2014;10(11):1487–92.CrossRefGoogle Scholar
  16. 16.
    Lazaros G, Karavidas A, Spyropoulou M, Tsiachris D, Halapas A, Zacharoulis A, et al. The role of the immunogenetic background in the development and recurrence of acute idiopathic pericarditis. Cardiology. 2011;118(1):55–62.CrossRefGoogle Scholar
  17. 17.
    Maestroni S, Di Corato PR, Cumetti D, Chiara DB, Ghidoni S, Prisacaru L, et al. Recurrent pericarditis: autoimmune or autoinflammatory? Autoimmun Rev. 2012;12(1):60–5.CrossRefGoogle Scholar
  18. 18.
    Yang CA, Chiang BL. Inflammasomes and human autoimmunity: a comprehensive review. J Autoimmun. 2015;61:1–8.CrossRefGoogle Scholar
  19. 19.
    van Kempen TS, Wenink MH, Leijten EF, Radstake TR, Boes M. Perception of self: distinguishing autoimmunity from autoinflammation. Nat Rev Rheumatol. 2015;11(8):483–92.CrossRefGoogle Scholar
  20. 20.
    Muruve DA, Petrilli V, Zaiss AK, White LR, Clark SA, Ross PJ, et al. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature. 2008;452(7183):103–7.CrossRefGoogle Scholar
  21. 21.
    Ichinohe T, Pang IK, Iwasaki A. Influenza virus activates inflammasomes via its intracellular M2 ion channel. Nat Immunol. 2010;11(5):404–10.CrossRefGoogle Scholar
  22. 22.
    Nour AM, Reichelt M, Ku CC, Ho MY, Heineman TC, Arvin AM. Varicella-zoster virus infection triggers formation of an interleukin-1beta (IL-1beta)-processing inflammasome complex. J Biol Chem. 2011;286(20):17921–33.CrossRefGoogle Scholar
  23. 23.
    Rathinam VA, Jiang Z, Waggoner SN, Sharma S, Cole LE, Waggoner L, et al. The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat Immunol. 2010;11(5):395–402.CrossRefGoogle Scholar
  24. 24.
    Karatolios K, Moosdorf R, Maisch B, Pankuweit S. Cytokines in pericardial effusion of patients with inflammatory pericardial disease. Mediat Inflamm. 2012;2012:382082.CrossRefGoogle Scholar
  25. 25.
    Horneffer PJ, Miller RH, Pearson TA, Rykiel MF, Reitz BA, Gardner TJ. The effective treatment of postpericardiotomy syndrome after cardiac operations. A randomized placebo-controlled trial. J Thorac Cardiovasc Surg. 1990;100(2):292–6.PubMedGoogle Scholar
  26. 26.
    Imazio M, Bobbio M, Cecchi E, Demarie D, Demichelis B, Pomari F, et al. Colchicine in addition to conventional therapy for acute pericarditis. Results of the COlchicine for acute PEricarditis (COPE) trial. Circulation. 2005;112(13):2012–6.CrossRefGoogle Scholar
  27. 27.
    Imazio M, Bobbio M, Cecchi E, et al. Colchicine as first-choice therapy for recurrent pericarditis: results of the core (colchicine for recurrent pericarditis) trial. Arch Intern Med. 2005;165(17):1987–91.CrossRefGoogle Scholar
  28. 28.
    Imazio M, Brucato A, Cemin R, Ferrua S, Maggiolini S, Beqaraj F, et al. A randomized trial of colchicine for acute pericarditis. N Engl J Med. 2013;369(16):1522–8.CrossRefGoogle Scholar
  29. 29.
    Verma S, Eikelboom JW, Nidorf SM, Al-Omran M, Gupta N, Teoh H, et al. Colchicine in cardiac disease: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2015;15(1):96.CrossRefGoogle Scholar
  30. 30.
    Adler Y, Charron P, Imazio M, Badano L, Baron-Esquivias G, Bogaert J, et al. ESC guidelines for the diagnosis and management of pericardial diseases. Rev Esp Cardiol (Engl Ed). 2015;68(12):1126.CrossRefGoogle Scholar
  31. 31.
    Leung YY, Yao Hui LL, Kraus VB. Colchicine-update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015;45(3):341–50.CrossRefGoogle Scholar
  32. 32.
    Imazio M, Brucato A, Cumetti D, Brambilla G, Demichelis B, Ferro S, et al. Corticosteroids for recurrent pericarditis. High versus low doses: a nonrandomized observation. Circulation. 2008;118(6):667–71.CrossRefGoogle Scholar
  33. 33.
    Imazio M, Brucato A, Trinchero R, Shabetai R, Spodick D, Adler Y. Corticosteroid therapy for pericarditis: a double-edged sword. Nat Clin Pract Cardiovasc Med. 2008;5(3):118–9.CrossRefGoogle Scholar
  34. 34.
    Vianello F, Cinetto F, Cavraro M, Battisti A, Castelli M, Imbergamo S, et al. Azathioprine in isolated recurrent pericarditis: a single centre experience. Int J Cardiol. 2011;147(3):477–8.CrossRefGoogle Scholar
  35. 35.
    Lennard L. Implementation of TPMT testing. Br J Clin Pharmacol. 2014;77(4):704–14.CrossRefGoogle Scholar
  36. 36.
    Imazio M, Lazaros G, Picardi E, Vasileiou P, Carraro M, Tousoulis D, et al. Intravenous human immunoglobulins for refractory recurrent pericarditis: a systematic review of all published cases. J Cardiovasc Med. 2016;17(4):263–9.CrossRefGoogle Scholar
  37. 37.
    Brucato A, Imazio M, Gattorno M, et al. Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence: the airtrip randomized clinical trial. JAMA. 2016;316(18):1906–12.CrossRefGoogle Scholar
  38. 38.
    Lazaros G, Antonatou K, Vassilopoulos D. The therapeutic role of Interleukin-1 inhibition in idiopathic recurrent pericarditis: current evidence and future challenges. Front Med. 2017;4:78.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Division of Rheumatology, Allergy and ImmunologyStony Brook UniversityStony BrookUSA

Personalised recommendations